(firstQuint)Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease.

 Once-weekly Prozac is a psychiatric medicine, approved by the FDA for the use in treatment of psychiatric disorders.

 This study will test whether once-weekly Prozac leads to reduced symptoms of depression.

 Patients requiring dialysis often report symptoms of depression either due to the presence of major depression, a relatively common psychiatric disorder, or due to depression secondary to kidney failure.

.

 Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease@highlight

The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.

